1. Home
  2. MIRM vs DV Comparison

MIRM vs DV Comparison

Compare MIRM & DV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • DV
  • Stock Information
  • Founded
  • MIRM 2018
  • DV 2008
  • Country
  • MIRM United States
  • DV United States
  • Employees
  • MIRM N/A
  • DV N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • DV Computer Software: Prepackaged Software
  • Sector
  • MIRM Health Care
  • DV Technology
  • Exchange
  • MIRM Nasdaq
  • DV Nasdaq
  • Market Cap
  • MIRM 1.9B
  • DV 2.2B
  • IPO Year
  • MIRM 2019
  • DV 2021
  • Fundamental
  • Price
  • MIRM $44.27
  • DV $13.34
  • Analyst Decision
  • MIRM Strong Buy
  • DV Buy
  • Analyst Count
  • MIRM 10
  • DV 18
  • Target Price
  • MIRM $60.80
  • DV $19.08
  • AVG Volume (30 Days)
  • MIRM 425.9K
  • DV 2.3M
  • Earning Date
  • MIRM 05-07-2025
  • DV 05-08-2025
  • Dividend Yield
  • MIRM N/A
  • DV N/A
  • EPS Growth
  • MIRM N/A
  • DV N/A
  • EPS
  • MIRM N/A
  • DV 0.29
  • Revenue
  • MIRM $379,251,000.00
  • DV $681,128,000.00
  • Revenue This Year
  • MIRM $29.51
  • DV $13.06
  • Revenue Next Year
  • MIRM $20.27
  • DV $12.77
  • P/E Ratio
  • MIRM N/A
  • DV $45.55
  • Revenue Growth
  • MIRM 69.31
  • DV 15.30
  • 52 Week Low
  • MIRM $23.83
  • DV $11.52
  • 52 Week High
  • MIRM $54.23
  • DV $23.11
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 56.45
  • DV 48.38
  • Support Level
  • MIRM $40.00
  • DV $13.16
  • Resistance Level
  • MIRM $47.43
  • DV $13.63
  • Average True Range (ATR)
  • MIRM 2.07
  • DV 0.44
  • MACD
  • MIRM 0.54
  • DV 0.19
  • Stochastic Oscillator
  • MIRM 65.27
  • DV 52.15

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About DV DoubleVerify Holdings Inc.

DoubleVerify Holdings Inc is a digital media measurement and analytics software platform. Its solutions provide advertisers with unbiased data analytics that enable them to increase the effectiveness, quality, and return on their digital advertising investments. Its DV Authentic Ad, a proprietary metric of digital media quality, measures whether a digital ad was delivered in a brand-suitable environment, fully viewable, by a real person, and in the intended geography. The company's software interface, DV Pinnacle, delivers these metrics to customers in real time, allowing them to access critical performance data on their digital transactions. Geographically, the company operates in the United States and also has a presence in Germany, Singapore, France, Canada, Japan, and other countries.

Share on Social Networks: